D. Boral Capital Reiterates “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV)
D. Boral Capital reissued their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) in a research note published on Monday,Benzinga reports. The brokerage currently has a $13.00 price target on the stock. Separately, HC Wainwright boosted their price objective on Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” […]
D. Boral Capital reissued their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) in a research note published on Monday,Benzinga reports. The brokerage currently has a $13.00 price target on the stock. Separately, HC Wainwright boosted their price objective on Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” […]